NLS Pharmaceutics (NASDAQ:NCEL) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of NLS Pharmaceutics (NASDAQ:NCEL) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of NLS Pharmaceutics in a research report on Tuesday, October 14th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, NLS Pharmaceutics presently has an average rating of “Sell”.

NLS Pharmaceutics Stock Performance

Shares of NCEL opened at $3.49 on Friday. The business’s fifty day moving average price is $15.48 and its 200 day moving average price is $19.37. NLS Pharmaceutics has a 12-month low of $3.26 and a 12-month high of $37.20.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).